Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar Haugurafpeningum (83.35) Submitted: 11/8/2011 2:28:44 AM : Outperform Start Price: $23.23 ACOR Score: -6.87

Technical Monthly

Featured Broker Partners


Advertisement